- Home
- PLX vs ARQ Comparison
PLX vs ARQ Comparison
Compare PLX & ARQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- ARQ
- Stock Information
- Founded
- PLX 1993
- ARQ 1996
- Country
- PLX United States
- ARQ United States
- Employees
- PLX N/A
- ARQ N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- ARQ
- Sector
- PLX Health Care
- ARQ
- Exchange
- PLX Nasdaq
- ARQ NYSE
- Market Cap
- PLX 160.2M
- ARQ 155.3M
- IPO Year
- PLX 1998
- ARQ N/A
- Fundamental
- Price
- PLX $2.87
- ARQ $3.56
- Analyst Decision
- PLX Strong Buy
- ARQ Strong Buy
- Analyst Count
- PLX 1
- ARQ 1
- Target Price
- PLX $15.00
- ARQ $8.00
- AVG Volume (30 Days)
- PLX 753.1K
- ARQ 232.2K
- Earning Date
- PLX 05-09-2025
- ARQ 05-07-2025
- Dividend Yield
- PLX N/A
- ARQ N/A
- EPS Growth
- PLX N/A
- ARQ N/A
- EPS
- PLX 0.04
- ARQ N/A
- Revenue
- PLX $53,399,000.00
- ARQ $114,466,000.00
- Revenue This Year
- PLX $65.02
- ARQ $19.26
- Revenue Next Year
- PLX $57.34
- ARQ $24.97
- P/E Ratio
- PLX $79.67
- ARQ N/A
- Revenue Growth
- PLX N/A
- ARQ 14.33
- 52 Week Low
- PLX $0.82
- ARQ $3.34
- 52 Week High
- PLX $3.10
- ARQ $8.26
- Technical
- Relative Strength Index (RSI)
- PLX 56.85
- ARQ 40.35
- Support Level
- PLX $2.70
- ARQ $3.58
- Resistance Level
- PLX $2.64
- ARQ $4.40
- Average True Range (ATR)
- PLX 0.17
- ARQ 0.26
- MACD
- PLX -0.01
- ARQ 0.05
- Stochastic Oscillator
- PLX 61.67
- ARQ 20.75
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About ARQ ARQ INC
Arq Inc is an environmental technology company principally engaged in the sale of consumable air, water, and soil treatment solutions including activated carbon (AC) and chemical technologies. The company manufactures and sells activated carbon and other chemicals used to capture and remove contaminants for the coal-fired power generation, industrial, municipal water and air, water and soil treatment and remediation markets. Some of the products in its portfolio are Powdered Activated Carbon, Granula Activated Carbon, and Colloidal Carbon Product among others.